Skip to main content
Clinical Trials/NCT02933333
NCT02933333
Unknown
Phase 4

G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine7 sites in 1 country405 target enrollmentSeptember 27, 2016

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Acute Myeloid Leukemia
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Enrollment
405
Locations
7
Primary Endpoint
assess the incidence of infection in patients after chemotherapy
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to explore the effect of G-CSF combination with GM-CSF on prevention and treatment of infection in children with malignant tumor.

Detailed Description

G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor.

Registry
clinicaltrials.gov
Start Date
September 27, 2016
End Date
December 2020
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Xiaojun Yuan

chief physician

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Patients with malignant tumor including acute myeloid leukemia (AML) after complete remission, acute lymphocytic leukemia (ALL) after complete remission, stage III or IV lymphoma after partial remission or complete remission, stage III or IV neuroblastoma (NB) or retinoblastoma (RB).
  • Eastern Cooperative Oncology Group performance status ≤
  • Did not receive treatment of CSFs in two weeks.
  • Without symptomatic infection and with normal values of C-reactive protein or procalcitonin.
  • The first time of ANC \< 1.5\*10\^9/L after chemotherapy.
  • More than 24 h after the last chemotherapy.
  • The function of liver was normal.

Exclusion Criteria

  • Allergic to GM-CSF or drugs which expressed in Escherichia coli.
  • Patients with infection, diabetes or primary immunodeficiency.
  • Patients infected with hepatitis B, hepatitis C or HIV.
  • Patients confirmed autoimmune thrombocytopenic purpura.

Outcomes

Primary Outcomes

assess the incidence of infection in patients after chemotherapy

Time Frame: within 20 days after chemotherapy

Study Sites (7)

Loading locations...

Similar Trials